- Home
- EYPT vs GTY Comparison
EYPT vs GTY Comparison
Compare EYPT & GTY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EYPT | GTY |
|---|---|---|
| Founded | 1987 | 1955 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Real Estate |
| Sector | Industrials | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | 2005 | 1998 |
Fundamental Metrics
Financial Performance| Metric | EYPT | GTY |
|---|---|---|
| Price | $18.29 | $33.08 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 5 |
| Target Price | $28.75 | ★ $31.60 |
| AVG Volume (30 Days) | ★ 1.6M | 644.5K |
| Earning Date | 03-23-2026 | 05-14-2026 |
| Dividend Yield | N/A | ★ 5.91% |
| EPS Growth | N/A | ★ 8.00 |
| EPS | N/A | ★ 1.35 |
| Revenue | $7,539,000.00 | ★ $221,727,000.00 |
| Revenue This Year | N/A | $8.03 |
| Revenue Next Year | N/A | $6.40 |
| P/E Ratio | ★ N/A | $24.35 |
| Revenue Growth | N/A | ★ 9.02 |
| 52 Week Low | $3.91 | $25.39 |
| 52 Week High | $19.11 | $34.02 |
Technical Indicators
Market Signals| Indicator | EYPT | GTY |
|---|---|---|
| Relative Strength Index (RSI) | 67.28 | 66.53 |
| Support Level | $11.88 | $28.17 |
| Resistance Level | $19.06 | $34.02 |
| Average True Range (ATR) | 1.27 | 0.66 |
| MACD | 0.54 | 0.01 |
| Stochastic Oscillator | 90.58 | 72.73 |
Price Performance
Historical ComparisonAbout EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses on developing and commercializing innovative therapeutics for serious retinal diseases. It develops therapies for serious retinal diseases to provide durable treatments that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained release product candidate for retinal diseases with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
About GTY Getty Realty Corporation
Getty Realty Corp is the real estate investment trust in the U.S. specializing in the acquisition, financing, and development of convenience, automotive, and other single tenant retail real estate. The company's portfolio includes convenience stores, car washes, automotive service centers (gasoline and repair, oil and maintenance, tire and battery, collision), automotive parts retailers, and certain other freestanding retail properties, including drive-thru quick service restaurants. It generates majority of the revenue in the form of rental income.